These modifications were designed to reduce binding affinity for IGF binding proteins (IGFBPs), which normally sequester circulating IGF-1 and limit its bioavailability
These conditions include aging and age-associated chronic muscle conditions such as cachexia 248 , sarcopenia 124,249,250 , inclusion body myositis (IBM) 114,251,252 , and neuromuscular diseases like Duchennes muscular dystrophy (DMD) 253,254
[26] The same critics claimed that previous controlled trials "found no evidence that chelation is superior to placebo for treatment of CAD [Coronary Artery Disease] or PVD [Peripheral Vascular Disease]," making the trial "unethical, dangerous, pointless, and wasteful." [3] Evidence of insurance fraud and other felony convictions among (chelation proponent) investigators further undermined the credibility of the trial
For example GSH has been shown to be important for the regulation of cellular labile copper pools 116
Growth hormone release peaks 90120 minutes after sleep onset, creating an anabolic signaling environment that prioritizes nitrogen retention and protein synthesis over fat oxidation